CDNA has formed a nice cup and handle pattern. The cup and handle target is around $50 near the top of the red channel within the larger white channel. With the big analyst upgrades this stock has been receiving CDNA could break the red channel to the upside and continue up the white channel.
Higher than avg vol today, following outside day candle. Perhaps we finally see low $40's on the horizon.
We're long since $31, looking for a target of low $40's This position has surely tested our patience but still green.
Short and simple pattern coming up here, 5-7% gain and with how the stock market has been I may just take it, hopefully I see a small pullback to confirm and get in on it.
CDNA - looking to retest $5.50/$5.53 before it can make a run to $6.29 range.
Consolidation of volume, RSI waiting to make a move, breakout of the falling wedge, the candlestick, to me on this day 03/01, shows me that ultimately there's an agreement in price. However, almost a $0.50 swing here as well, as investors begin to stare each other down.
Let's see what...
Lots of noise caused me to miss my prediction; trust your charting process and watch profits grow. Blue vertical line is where i started watching my play. To the penny it did what i predicted, but i didn't pull the trigger.
After a 153.77% run in 3 months, CDNA has entered into a nice consolidation pattern which it is currently near the bottom of. This trade has great risk/reward of 3.5
Entry: 2.69
Stop Loss: 2.58
Initial Profit Target: 3.08
Depending on how to stock acts near its all time highs, I will decide to continue to hold for a breakout or sell and take profits
CDNA
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
CDNA
